Leishmaniasis - A Pipeline Analysis Report

This pipeline analysis report provides detailed insights into the clinical trials landscape of the drug development for leishmaniasis including molecules at pre-clinical and discovery stage. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as therapy, route of administration, by territory, therapeutic modality, and target.

Overview of the drug development pipeline for leishmaniasis  

Caused by the parasites of Leishmania species, Leishmaniasis is transmitted through the bites of sandflies. Globally, the disease is rampant in around 60 countries including Southern Europe, North Africa, the Middle East, Central and South America, and the Indian subcontinent. Countries such as South East Asia and Australia are the least affected regions by leishmaniasis. In 2017, several companies formed a consortium for the treatment for leishmaniasis. These companies will share their newly identified potential drug compound or molecule with DNDi, to aid in developing new drugs to treat leishmaniasis. Technavio’s market research analysts identify the Drugs for Neglected Diseases Initiative (DNDi) investing and focusing on developing new treatments for neglected diseases. This non-profit research and development organization collaborates with numerous pharmaceutical companies to develop a low-cost for the treatment for neglected diseases.

According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the discovery drug development stage followed by pre-clinical drug development stage. Our market research analysts have also identified that almost same amount of drug molecules is under the phase I and phase II drug development stage.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug development molecules for the treatment of leishmaniasis. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are:

• ETNA BIOTECH
• IMMUNE MODULATION
• MOLECULAR TARGETING TECHNOLOGIES

Therapeutic assessment of the drug development pipeline for leishmaniasis by route of administration

• Oral

The oral route of administration (ROA) involves the administration of drug substances through mouth cavity. It has been observed that a total of 5 therapeutics for are being developed for oral administration.

Therapeutic assessment of the drug development pipeline for leishmaniasis by therapeutic modalities

• Small molecules
• Biologicals
• Vaccine

According to this pipeline analysis report, majority of the molecules being developed in the drug development pipeline for leishmaniasis are small molecules. The current pipelines consist of seven molecules that are being developed as small molecules. These molecules are chemically manufactured active substances that bind with specific biological macromolecules and act as an effector and alter the activity of the target cell.  

Technavio also offers customization on reports based on specific client requirement.